Amgen is the world's biggest independent biotechnology developer, and was one of the original pioneers in that sector in the 1983 with the development of Epogen, a synthetic form of the hormone that controls red blood cell production. Unlike many of its biotech competitors it avoided the temptation to be acquired by one of larger traditional pharma companies, but now ranks among them by annual revenues, partly as a result of several acquisitions of its own. It has built up a small but important drug portfolio which currently houses seven billion-dollar blockbusters. These are led by arthritis and psoriasis treatment Enbrel. Amgen generated sales of $5.0bn from Enbrel in North America in 2018 - Pfizer has rights elsewhere - but sales are now in decline as various patents come due for expiry. It is accompanied by white blood cell stimulator Neulasta (sales of $4.5bn), Xgeva and Prolia for osteoporosis (combined sales of $4.1bn), Aranesp ($1.9bn) and Sensipar/Mipara ($1.8bn). Amgen's founding product Epogen still contributed sales just over $1.0bn in 2018. In 2013, Amgen agreed to acquire smaller rival Onyx, developer of blood cancer treatment Kyprolis, for $10.4bn. It is likely to make blockbuster status in 2019. Sales in 2018 were $968. Also in 2019, Amgen acquired the psoriasis drug Otezla - sales of $1.6bn in 2018 - from Celgene for $13.4bn. The company has a longstanding development partnership with Japanese drinks company Kirin, whose pharmaceuticals division was one of the original marketing partners for Epogen. Robert Bradway is chairman & CEO. Group revenues for 2018 were $23.7bn. Net income reached a best-ever $8.4bnThe group was founded in 1980 as an experimental biotech famility under the name Applied Molecular Genetics. It adopted the abbreviated Amgen name in 1983.
Capsule checked 27th August 2019
Who handles advertising for Amgen? Find out more from the Adbrands Account Assignments database
Who are the competitors of Amgen? see Pharmaceutical Sector index
Adbrands Account Assignments is a database tracking account management for the world's leading brands and companies. In other words, which advertising agency handles which accounts in which countries. Fully searchable by brand, brandowner company or advertising agency, the database now contains more than 15,000 worldwide account assignments for over 4,000 leading brands.
Recent stories from Adbrands Update:
Adbrands Daily Update 27th Aug 2019: Amgen has agreed to acquire the psoriasis drug Otezla from rival Celgene for $13.4bn in cash, a little over eight times the drug's 2018 sales. The purchase coincides with the expiry by Amgen's lead drug Enbrel of one of its original patents for the treatment of psoriasis. Otezla is likely to have another ten years before its own patents terminate. The sale by Celgene will also clear one of the main obstacles identified by regulators in its proposed acquisition by Bristol-Myers Squibb.
Adbrands Weekly Update 24th May 2018: Trade source Fierce Pharma has compiled an interesting table of the top drugs sold in the US over the past 25 years, using cumulative sales figures. It passed its peak several years ago now, but Pfizer's cholesterol drug Lipitor is still the clear leader with total sales to-date of almost $95bn. It could soon be toppled, though, by AbbVie's Humira, a treatment for auto-immune conditions. Sales are already almost $76bn, and Humira is expected to become the first drug ever to top $20bn in sales in a single year before its patent expires in 2023. In third place for now is Nexium, from AstraZeneca, for acid reflux and ulcers. It too is past its peak, but cumulative sales currently stand at over $72bn. GSK's Advair and Amgen's Enbrel rounded out the top five at $69bn and $68bn respectively. (See full feature here).
Adbrands Weekly Update 22nd Mar 2018: Another week, another loss for struggling Wavemaker. Pharma group Amgen is to transfer its $350m US media account to Omnicom's Hearts & Science agency. The business was previously split between Wavemaker's predecessor MEC and Omnicom's specialist healthcare media unit SSCG, which will retain its share of B2B duties. Amgen's drugs include Enbrel, Neulasta and Neupogen.
Adbrands Weekly Update 29th Aug 2013: US pharmaceutical group Amgen, the global leader in hard-to-copy biotech drugs, announced a $10.4bn deal to acquire smaller rival Onyx, whose blood cancer treatment Kyprolis is forecast to top sales of $1bn by 2015. The deal will plug an expected hole in Amgen's product pipeline - its current top-sellers Neulasta and Neupogen will have passed their peak by 2015, while newer drugs in development may not be out of clinical trials.
All rights reserved © Mind Advertising Ltd 1998-2019